Trial Profile
A Randomized, Double Blind, Comparative, Phase I Study To Evaluate The Safety, Tolerability And Immunogenicity Of Three Formulations (15µg Without Adjuvant, 7.5µg With Adjuvant And 3.75µg With Adjuvant) Of Monovalent H1N1 Influenza A (2009) Virus Vaccine In Healthy Adults. - H1N1Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; Adjuvants
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Panacea Biotec
- 13 Feb 2010 New trial record